Robbins LLP Alerts Investors to Mereo BioPharma Lawsuit
Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Mereo BioPharma Group plc. (NASDAQ: MREO)...
Tag : biopharmaceutical company
Aera Technology’s Decision Intelligence Cuts Supply Chain Waste by 20%
Optimizes and Automates Decisions That Reduce Inventory Waste, Prevent Obsolescence, and Advance Sustainability Aera Technology, creator of the first decision intelligence agent, Aera, and a leader...
Innovent & HUTCHMED NDA Accepted for Sintilimab Combo in China
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...
InnoCare Gets OK to Trial Mesutoclax for MDS in China
InnoCare Pharma, a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the approval of the Investigational New Drug (IND)...
Rznomics Partners with Eli Lilly for RNA-editing Therapeutics Licensing
Co-development of precision RNA therapeutics for inherited hearing loss treatment Rznomics Inc., a South Korea-based biopharmaceutical company specializing in RNA-based therapeutics, announced today that it has...
iOnctura commences randomized Phase I/II study in non-small cell lung cancer
iOnctura, a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers, today announces it has dosed the first patient in the randomized Phase I/II study investigating...
Alchemab signs $415M licensing deal for ATLX-1282 with Eli Lilly
New agreement with Lilly to license ATLX-1282, a first-in-class IND-ready programme for neurodegenerative conditions targeting a novel receptor and mechanism Deal worth up to $415m including upfront...
InnoCare’s Zurletrectinib Receives Priority Review from China’s NMPA
InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company for the treatment of cancer and autoimmune diseases, announced today that its new generation pan-TRK inhibitor zurletrectinib...
Innovent Doses First Patient in Phase 1 Trial of IBI3020 ADC
Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology...
AbolerIS Pharma Announces Formation of Scientific Advisory Board
AbolerIS Pharma (“AbolerIS”), a clinical-stage biopharmaceutical company committed to improving the lives of people suffering from autoimmune and inflammatory diseases, today announced the formation of...
NEJM Publishes Positive Phase 3 Brensocatib Data from Insmed
Largest Global Clinical Trial Ever Conducted in Bronchiectasis Demonstrates Statistically Significant and Clinically Meaningful Reduction in Frequency of Pulmonary Exacerbations Versus Placebo Brensocatib 25 mg...
Scholar Rock Grants Employee Inducement Awards Under Nasdaq Rule
Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases, today...
Precigen & RRP Foundation to Host 2025 RRP Awareness Day
– International event will raise awareness and bring together RRP patients, caregivers, and the healthcare community supporting them –– Recurrent respiratory papillomatosis is a rare, debilitating, chronic...
Boehringer Ingelheim, Cue Biopharma Partner on Autoimmune Therapies
Boehringer Ingelheim and Cue Biopharma, Inc. (Nasdaq: CUE) today announced a strategic research collaboration and license agreement to develop and commercialize Cue Biopharma’s CUE-501 product candidate, a...
Oculis Hosts R&D Event to Share Pipeline Progress Today
Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with...